CSTL - Castle Biosciences, Inc.
About Castle Biosciences, Inc. (https://castlebiosciences.com)
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President & Director | 1962 | $1,809,563 USD |
| Frank Stokes | Chief Financial Officer & Treasurer | 1970 | $1,001,919 USD |
| Kristen Oelschlager | Chief Operating Officer | 1969 | $944,652 USD |
| Tobin W. Juvenal | Chief Commercial Officer | 1961 | $944,652 USD |
| Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs | – | – |
| Hillary Caruso | Chief of Staff | – | – |
| Jay Braxton | Vice President of Marketing & Brand Manager of Uveal Melanoma (UM) | – | – |
| Keli Greenberg | Vice President of Human Resources | – | – |
| Kevin Doman | Vice President of Sales | – | – |
| Matthew Goldberg | Senior Vice President of Medical | – | – |
| Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations | – | – |